$2.1 million is a very good base from which to grow ADAPT sales and there's many reasons why this quarter will be much higher....
-Full launch of CardioCel3D in US.
-Indian launch
-Jordan launch
-The December quarter is typically a down quarter due to Christmas and holidays.
- "This growth occurred in spite of major field force reshuffles in the EU and US with many territories left vacant during the quarter. Territories that had consistent sales representation saw growth of 100% further validating both the clinical superiority of our products as well as the commercial model." -WP
I believe these reshuffles now to be complete and this will add substantially to this quarters revenues.
$2.1 million is a very good base from which to grow ADAPT sales...
-
- There are more pages in this discussion • 120 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add AVR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$14.25 |
Change
0.740(5.48%) |
Mkt cap ! $301.2M | |||
| Open | High | Low | Value | Volume |
| $13.60 | $14.25 | $13.35 | $309.6K | 22.39K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 1150 | $14.10 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $14.25 | 314 | 1 |
View Market Depth
| Last trade - 16.10pm 09/08/2024 (20 minute delay) ? |
| AVR (ASX) Chart |